Lilly sells constipation drug to Adolor

  • Comments
  • Print

Biotechnology company Adolor Corp. said yesterday that it bought exclusive worldwide rights to Eli Lilly and Co.’s OpRA
III drug candidate, which has a range of potential uses.

Exton, Pa.-based Adolor will pay $2 million upfront to
Indianapolis-based Eli Lilly, along with future royalties and milestone payments potentially worth $70 million.

said it initially intends to develop the drug candidate as a potential opioid bowel-dysfunction treatment and will start clinical
trials in early 2010. The condition normally refers to chronically constipated patients taking opioid pain drugs.

Please enable JavaScript to view this content.

Story Continues Below

Editor's note: You can comment on IBJ stories by signing in to your IBJ account. If you have not registered, please sign up for a free account now. Please note our updated comment policy that will govern how comments are moderated.